In Brief

An agent that improves survival in metastatic breast cancer patients has been launched. Herceptin (trastuzumab), a humanised monoclonal antibody, suppresses tumour growth in the 20-30 per cent of metastatic breast cancer patients who overproduce a growth factor called HER2. It binds HER2 receptors on the cancer cell surface so that ...

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • 10 expert briefings every fortnight (Premium only)
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

Already a subscriber? Sign into your account here